Healthy volunteers help test new combo pill for heart health
NCT ID NCT06889012
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage study tested how the body processes three experimental drugs (BR1018, BR1018A, and BR1018B) in 60 healthy adults. The goal was to measure drug levels and check safety, not to treat any condition. Results will guide future studies for high blood pressure and high cholesterol.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- BR1018, BR1018A, BR1018B (drug tablets)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
60 people
The number who actually took part.
- Started
-
May 2025
- Finished
-
Jul 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
19 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Those who have body mass index (BMI) of more than 18.0kg/m2 and less than 30.0kg/m2 at screening visit. * For men, Those who weigh 50 kg or more * For women, Those who weigh 45 kg or more * Those who sign written consent spontaneously after listening to and understanding sufficient explanation of the purpose and contents of this clinical trial, characteristics of the Investigational products, expected adverse events, etc. * Those who agree to rule out the possibility of their and their spouses' or sexual partners' pregnancy by using methods of contraception accepted in clinical trial\*(Except for hormone drugs) from the date of consent to 14 days after the last administration and disagree to provide their sperm or ovum. * Methods of contraception accepted in clinical trial: Combined use of intrauterine device, vasectomy, tubal ligation, and barrier methods (male condom, female condom, cervical cap, contraceptive diaphragm, sponge, etc.) or combined use of two or more barrier methods if spermicide is used. Exclusion Criteria: * Those who have taken drugs that induce and inhibit metabolizing enzymes such as barbiturate within 30 days before the first administration date or have taken drugs concerned about affecting this clinical trial within 10 days before the first administration date. (However, participation is possible considering pharmacokinetics and pharmacodynamics such as Interaction of investigational products, half-life of concomitant drugs, etc.) * Those who have a medical history of gastrointestinal resection or gastrointestinal diseases that may affect the absorption of drugs. (Except for simple appendectomy, hernia surgery) * Those who have participated in other clinical trials(including bioequivalence tests) and administered their investigational products within 6 months before the first administration date. (However, the termination for participation in other clinical trials are based on the last administration date of their investigational products) * Those who can't discontinue a diet (ex. raw grapefruit, grapefruit juice or food containing grapefruit, etc.) that may affect the absorption, distribution, metabolism, and excretion of the drug within 48 hours before the first administration date * In the case of a female subject, those suspected pregnancy or pregnant woman or lactating woman.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Essential hypertension are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Clinical Research Center, H PLUS Yangji Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill crack the code of stubborn high blood pressure?
- Can one shot tame high blood pressure?
- Can a Two-Pill combo tame stubborn high cholesterol?
- Can a new pill tame blood pressure that Won't budge?
- Can one pill tame both blood pressure and blood sugar?
- Could a heart drug be a new key to controlling high blood pressure?